Loading chat...
NY A03236
Bill
Status
1/27/2025
Primary Sponsor
Jenifer Rajkumar
Click for details
AI Summary
-
Directs the Commissioner of Health to enter into partnerships with drug manufacturers, other state agencies, and other states to produce and distribute generic prescription drugs at lower prices
-
Requires partnerships to include production of at least one form of insulin, provided a viable manufacturing pathway exists, and prioritizes drugs for chronic and high-cost conditions
-
Mandates all state agencies purchase generic prescription drugs from the department or its contracted partners
-
Requires drugs be made available at transparent prices without rebates (except federally required ones), with pricing based on FDA fees, production costs, R&D costs, and reasonable operating expenses
-
Department must submit a feasibility report on direct drug manufacturing to the legislature by January 1, 2028, and a status report on targeted drugs by March 1, 2027
Legislative Description
Enacts the "New York affordable drug manufacturing act" to direct the commissioner of health to enter into partnerships to increase competition, lower prices, and address shortages in the market for generic prescription drugs, to reduce the cost of prescription drugs for public and private purchasers, taxpayers, and consumers, and to increase patient access to affordable drugs.
Last Action
referred to health
1/7/2026